50916-55-7

Usage

Uses

Used in Pharmaceutical Research:
3-(2-Bromoacetyl)benzonitrile is used as a key intermediate in the synthesis of novel glycogen synthase kinase-3 (GSK-3) inhibitors. These inhibitors are of significant interest due to their potential as central nervous system agents, which can be utilized in the development of treatments for various neurological disorders and conditions.
Used in Chemical Synthesis:
As a light yellow solid with distinct chemical properties, 3-(2-Bromoacetyl)benzonitrile can be employed as a building block or reactant in the synthesis of other organic compounds. Its unique structure allows for further functionalization and modification, making it a valuable component in the creation of new molecules with specific applications in various industries.
Used in Material Science:
3-(2-Bromoacetyl)benzonitrile's chemical structure and properties may also find applications in material science, where it could be used to develop new materials with tailored properties. These materials could have potential uses in areas such as electronics, coatings, or adhesives, depending on the specific characteristics achieved through the incorporation of 3-(2-Bromoacetyl)benzonitrile.

InChI:InChI=1/C9H6BrNO/c10-5-9(12)8-3-1-2-7(4-8)6-11/h1-4H,5H2

Upstream product

• 6136-68-1 3-acethylbenzonitrile 
• 7726-95-6 bromine 

Downstream Products

• 92132-60-0 <4-(3-cyanophenyl)-2-thiazolyl>guanidine hydrobromide 
• 88304-58-9 3-(1H-imidazol-4-yl)benzonitrile 
• 92536-05-5 3-(2-Amino-1-hydroxy-ethyl)-benzonitrile 
• 166190-02-9 3-(2-Phenoxy-acetyl)-benzonitrile 
• 6136-68-1 3-acethylbenzonitrile 
• 83112-49-6 α-acetoxy-3-cyanoacetophenone 
• 474334-54-8 (Z)-4-Bromo-3-(3-cyano-phenyl)-2-fluoro-but-2-enoic acid ethyl ester 
• 431040-28-7 3-(2-Methylimidazol-1-yl-acetyl)-benzonitrile 
• 83112-77-0 m-cyanophenacyl azide 
• 956027-81-9 6-(3-cyanophenyl)-imidazo[2,1-b]thiazole 
• 1007232-83-8 3-{2-[(2-hydroxy-1,1-dimethylethyl)amino]-1,3-thiazol-4-yl}benzonitrile 
• 481049-57-4 C₁₄H₈ClN₃ 
• 79889-65-9 3-Benzo[d]imidazo[2,1-b]thiazol-2-yl-benzonitrile 
• 88304-64-7 3-1H-imidazol-4-ylbenzamidine 

Relevant academic research and scientific papers

Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents

Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of Mycobacterium tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed. An attractive target for the development of new antitubercular agents is the salicylate synthase MbtI, an essential enzyme for the mycobacterial siderophore biochemical machinery, absent in human cells. A set of analogues of I and II, two of the most potent MbtI inhibitors identified to date, was synthesized, characterized, and tested to elucidate the structural requirements for achieving an efficient MbtI inhibition and a potent antitubercular activity with this class of compounds. The structure-activity relationships (SAR) here discussed evidenced the importance of the furan as part of the pharmacophore and led to the preparation of six new compounds (IV-IX), which gave us the opportunity to examine a hitherto unexplored position of the phenyl ring. Among them emerged 5-(3-cyano-5-(trifluoromethyl)phenyl)furan-2-carboxylic acid (IV), endowed with comparable inhibitory properties to the previous leads, but a better antitubercular activity, which is a key issue in MbtI inhibitor research. Therefore, compound IV offers promising prospects for future studies on the development of novel agents against mycobacterial infections.

Based on isoxazole substitution of benzamide derivatives and anti-prostate cancer drug applications

The present invention discloses a class (I), formula (II) structure based on isoxazole substituted benzamide derivatives and antiprostate cancer drug applications, such isoxazole substituted benzamide derivatives, can effectively inhibit the activity of a

Synthesis and anti-inflammatory activity of 1,2-3-substituted 2a1,4,5-triazacyclopenta[cd]indene derivatives

The present study reports the synthesis of 1,2-3-substituted-2a1,4,5-triazacyclopenta[cd]indene derivatives. The synthetic methodology includes some of the prominent reaction steps as specified in sequence (i) Bromination of acetophenones (ii) Condensation of 2-bromo-1-(substituted phenyl) ethanone derivatives with 2-aminopyrimidine, and (iii) Coupling of imidazo[1,2-a]pyrimidine derivatives with 1,2-diaryl/diaklylethynes. The structures of the newly synthesized derivatives have been determined by 1H NMR, 13C NMR, LC-MS, and IR spectral analysis. Furthermore, these derivatives were screened for their preliminary anti-inflammatory activities using Carrageenan induced paw edema test method. These promising screening results suggested a huge potential for the molecular diversity from present compounds that can be inflated to better lead candidates.

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

COMPOUNDS USEFUL AS RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS

Disclosed are retinoid-related orphan receptor gamma (RORγ) modulators of Formula (I) and their use in the treatment of diseases mediated by RORγ, wherein the radicals have the meanings as defined in the invention.

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: Clues for specific design of new compounds

Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, being one of the inhibitors on clinical trials for different tauopathies. Following our hypothesis based on the enhanced reactivity of residue Cys199 in the binding site of GSK-3, we examine here the suitability of phenylhalomethylketones as irreversible inhibitors. Our data confirm that the halomethylketone unit is essential for the inhibitory activity. Moreover, addition of the halomethylketone moiety to reversible inhibitors turned them into irreversible inhibitors with IC50 values in the nanomolar range. Overall, the results point out that these compounds might be useful pharmacological tools to explore physiological and pathological processes related to signaling pathways regulated by GSK-3 opening new avenues for the discovery of novel GSK-3 inhibitors.

CYTOKINE INHIBITORS

Provided is a compound of Formula (I): and/or at least one pharmaceutically acceptable salt thereof. Also provided are a method of inhibiting the activity of at least one protein chosen from TNFα, IL-1β, NF-κB, IL-10 and iNOS, a method of decreasing a lev

CYTOKINE INHIBITORS

A compound of Formula I: Each variable is defined in the specification. This invention relates to a method of decreasing a level of a cytokine (e.g., TNFα or interlukine such as IL-1β) in a subject with a compound of Formula I. It also relates to a method

A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential

The synthesis and SAR of 5-heterocycle-substituted aminothiazole adenosine receptor antagonists is described. Several compounds show high affinity and selectivity for the A2B and A3 receptors. One compound (5f) shows good ADME properties in the rat and as such may be an important new compound in testing the current hypotheses proposing a therapeutic role for a dual A2B/A3 antagonist in allergic diseases.

ANTIBACTERIAL BENZOIC ACID DERIVATIVES

The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.